Moving towards a universal hepatitis B vaccine program for Canadian children

By the early 1990s, evidence had accumulated that the selective hepatitis B vaccine strategy aimed at high risk individuals was failing to stem the tide of hepatitis B infection in Canada. The reported rates of acute hepatitis B and deaths due to hepatitis B infection had increased, not decreased, over the decade (1). Both the National Advisory Committee on Immunization and the Canadian Paediatric Society, on review of the data and examination of possible factors behind the failure of the selective vaccine program (2), endorsed the principle of universal childhood immunization (3,4).

The Canadian Hepatitis B Working Group, on reviewing the options (the status quo; universal infant program; universal preadolescent program; universal adolescent program), recommended that a preadolescent program be added to the current selective strategy to decrease the rate of new hepatitis B infection in Canada (5). Using American data, Bloom and colleagues (6) showed that the preadolescent school-based option is likely to be the most cost effective. This assessment is thought also to be valid in Canada since fewer than 3% of reported acute hepatitis B cases occur in early childhood, with the dramatic increase in incidence occurring in later adolescence and young adulthood. Given these demographics, sexual activity and possibly also injection drug use appear to be important factors for hepatitis B transmission in Canada (1,5).

Thus, to maximize the impact on the incidence of hepatitis B infection, a universal immunization program needs to begin before the onset of sexual activity. An adolescent program may be too late and a preadolescent program would have a shorter lag phase before accruing benefits than would an infant program. A preadolescent program has the added advantage of needing smaller doses of vaccine than an adult program while still offering protection before sexual activity becomes common.

British Columbia, the first province to introduce a universal preadolescent hepatitis B program, initiated a school-based program in 1992, which immunized over 90% of eligible 11-year-olds (7). Quebec, Yukon and Ontario followed suit with universal preadolescent school-based programs in 1994 aimed at grade 4 (Quebec and Yukon) and grade 7 (Ontario) students. Nova Scotia, New Brunswick, Newfoundland, Prince Edward Island, Alberta and the Northwest Territories are expected to have preadolescent school-based programs in place by the fall of 1995. New Brunswick, Prince Edward Island and the Northwest Territories have also started universal infant hepatitis B immunization programs in addition to the preadolescent programs.

While all of the provinces and territories that have started the universal school-based programs must be applauded, this single grade/age strategy has created some confusion for the general public. Why are older children and adolescents not being covered since they will be moving into the sexually active risk group sooner than the eligible preadolescents? Cost appears to have precluded catch-up programs for adolescents at the moment. To facilitate immunization for adolescents and young adults who missed out on the school program, physicians in practice are encouraged to offer hepatitis B immunization at cost through their offices. Both of the manufacturers of the currently licensed hepatitis B vaccines have bulk purchase programs available to physicians, which can lower the cost for families by negating the additional dispensing fee charges of retail pharmacies. Some parents may be able to have the cost covered though private insurance if the vaccine is purchased by prescription. The direct line for Merck Frosst Canada Inc for Recombivax is 1-800-268-4827, and the direct line to SmithKline Beecham Pharma Inc for Engerix B is 1-800-565-5468. In some provinces parents are also able to purchase vaccine at cost through their health department. Routine prevaccination screening for antibody is not recommended in this population because of the low prevalence of anti-HBs (hepatitis B surface antigen) (8). Post-vaccination testing for anti-HBs in healthy persons is also not

All material presented in Paediatric Infectious Disease Notes has been reviewed and approved by the chairperson, Canadian Paediatric Society Board and representative members of the Canadian Pediatric Society Committee on Infectious Diseases and Immunization.

Correspondence and reprints: Infectious Diseases and Immunization Committee, Canadian Paediatric Society, 401 Smyth Road, Ottawa, Ontario K1H 8L1. Telephone (613) 737-2728, Fax (613) 737-2794
recommended provided that the vaccine was administered properly (8).

The lack of universal ‘free’ catch-up programs is of concern. The longer the delay in achieving a universally immunized adolescent population, the more new cases of hepatitis B will likely occur and the less confidence the public will have in the program. Our provincial ministries of health must look closely at measures to expand coverage beyond these pre-adolescent school-based programs. Unfortunately, a universal health care system in which prevention programs receive high priority is still a long way from reality in Canada (9).

REFERENCES

NE MacDonald MD FRCPA
Chief, Division of Infectious Disease
Children’s Hospital of Eastern Ontario
Ottawa, Ontario

ADULT INFECTIOUS DISEASE NOTES

Confronting antibiotic-resistant organisms – A Canadian perspective

Antibiotic-resistant organisms (AROs) and with them the threat of new and reemergent infectious diseases are on the rise worldwide. This rising tide of resistance to antimicrobial drugs has been referred to as a ‘worldwide calamity’ (1). Since the beginning of this decade, clinicians, microbiologists and public health officials have confronted an unprecedented number of epidemics of ‘new’ infectious diseases and resurgent ‘old’ infectious diseases on a truly international scale. Examples are the hantavirus pulmonary syndrome in the United States, human T cell lymphotropic virus in the Caribbean, Sabin virus in Brazil, Guanarito virus in Venezuela, Escherichia coli O157:H7 disease and cryptosporidiosis in the United States, Vibrio cholerae O1 in Latin America and O139 in Asia, Rift Valley fever in Egypt, multidrug-resistant tuberculosis in Asia and the United States, bubonic plague in India, and AROs in Europe, Latin America and the United States (2,3). Of the reemerging infectious diseases, AROs arguably represent the most immediate threat to human health and welfare. The prospect and indeed reality of attempting to treat multiply drug-resistant enterococcal, pneumococcal and tuberculous infections have been brought to the attention of both the scientific community and the lay press (3-5). The most serious threat is the acquisition of resistance to vancomycin either by methicillin-resistant Staphylococcus aureus or by macrolide penicillin-resistant Streptococcus pneumoniae, which could create invasive clones for which there are few or no easily available therapeutic agents. The successful transfer and expression of vancomycin-resistant genes to S